Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052803516> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2052803516 endingPage "S699" @default.
- W2052803516 startingPage "S699" @default.
- W2052803516 abstract "Paclitaxel is an active drug for NSCLC. Our purpose was to evaluate the efficacy and toxicity of biweekly administration of this drug in previously treated patients with advanced NSCLC. Patients with stage IIIB and IV NSCLC, which progressed after or during first-line chemotherapy, measurable disease, ECOG PS=0-1 and adequate organ function were included. Paclitaxel was administered at 150 mg /m2 iv, days 1 and 14, every 28 days, for a maximum of six cycles. Both, toxicity and efficacy analyses, were performed on the intent-to-treat (ITT) population. Between September 2004 and November 2006, 45 patients (M/F, 42/3) were included, with median age 62 years (39-79). Tumor histology mainly included epidermoid (42.2%) and adenocarcinoma (35.6%). Tumor stage was IIIB (24.4%) and IV (75.6%). Median number of metastatic lesions was 1 (57.8%), located mainly in lymph nodes (44.4%), lung (33.3%), adrenal glands (20%) and bone (13.3%). Previous chemotherapy included platinum (80%), docetaxel (64.4%) and gemcitabine (57.8%). A total of 251 cycles (median 5, range 1-6) were administered. Median relative dose intensity was 96.2%. Toxicity: Grade III/IV hematologic toxicities per patient were neutropenia (2.3%) and anemia (2.3%). Grade III/IV non-hematologic toxicities were asthenia (2.3%), arthralgias/myalgias (2.3%) and peripheral neuropathy (2.3%). Efficacy: Of 45 ITT patients. 9 achieved PR, 11 SD and 17 progressed, resulting in an ORR of 20% (95%CI: 8.3-31.7%). 7 patients could not be evaluated due to early withdrawal (4 tumor-related exitus, 1 PS deterioration, 1 hypersensibility reaction and 1 loss of follow-up). With an average follow-up time of 286 days, median TTP and OS were 174 days (95%CI: 137.6-210.4) and 289 days (95%CI: 140.5-437.4), respectively. Biweekly paclitaxel is an active and very well tolerated regimen in previously treated patients with advanced NSCLC." @default.
- W2052803516 created "2016-06-24" @default.
- W2052803516 creator A5005936507 @default.
- W2052803516 creator A5006579116 @default.
- W2052803516 creator A5027407072 @default.
- W2052803516 creator A5032081954 @default.
- W2052803516 creator A5051222814 @default.
- W2052803516 creator A5057844864 @default.
- W2052803516 creator A5061802540 @default.
- W2052803516 creator A5066987855 @default.
- W2052803516 creator A5068676938 @default.
- W2052803516 creator A5089298509 @default.
- W2052803516 date "2007-08-01" @default.
- W2052803516 modified "2023-09-28" @default.
- W2052803516 title "P2-317: Biweekly paclitaxel as second-line treatment in advanced non-small-cell-lung-cancer (NSCLC). A phase II study of the Lung Cancer Galician Group" @default.
- W2052803516 doi "https://doi.org/10.1097/01.jto.0000284025.75029.e2" @default.
- W2052803516 hasPublicationYear "2007" @default.
- W2052803516 type Work @default.
- W2052803516 sameAs 2052803516 @default.
- W2052803516 citedByCount "0" @default.
- W2052803516 crossrefType "journal-article" @default.
- W2052803516 hasAuthorship W2052803516A5005936507 @default.
- W2052803516 hasAuthorship W2052803516A5006579116 @default.
- W2052803516 hasAuthorship W2052803516A5027407072 @default.
- W2052803516 hasAuthorship W2052803516A5032081954 @default.
- W2052803516 hasAuthorship W2052803516A5051222814 @default.
- W2052803516 hasAuthorship W2052803516A5057844864 @default.
- W2052803516 hasAuthorship W2052803516A5061802540 @default.
- W2052803516 hasAuthorship W2052803516A5066987855 @default.
- W2052803516 hasAuthorship W2052803516A5068676938 @default.
- W2052803516 hasAuthorship W2052803516A5089298509 @default.
- W2052803516 hasBestOaLocation W20528035161 @default.
- W2052803516 hasConcept C121608353 @default.
- W2052803516 hasConcept C126322002 @default.
- W2052803516 hasConcept C141071460 @default.
- W2052803516 hasConcept C2776256026 @default.
- W2052803516 hasConcept C2776694085 @default.
- W2052803516 hasConcept C2776907518 @default.
- W2052803516 hasConcept C2777063308 @default.
- W2052803516 hasConcept C2778239845 @default.
- W2052803516 hasConcept C2778248108 @default.
- W2052803516 hasConcept C2780258809 @default.
- W2052803516 hasConcept C2781182431 @default.
- W2052803516 hasConcept C2781190966 @default.
- W2052803516 hasConcept C2781451048 @default.
- W2052803516 hasConcept C2908647359 @default.
- W2052803516 hasConcept C29730261 @default.
- W2052803516 hasConcept C71924100 @default.
- W2052803516 hasConcept C90924648 @default.
- W2052803516 hasConcept C99454951 @default.
- W2052803516 hasConceptScore W2052803516C121608353 @default.
- W2052803516 hasConceptScore W2052803516C126322002 @default.
- W2052803516 hasConceptScore W2052803516C141071460 @default.
- W2052803516 hasConceptScore W2052803516C2776256026 @default.
- W2052803516 hasConceptScore W2052803516C2776694085 @default.
- W2052803516 hasConceptScore W2052803516C2776907518 @default.
- W2052803516 hasConceptScore W2052803516C2777063308 @default.
- W2052803516 hasConceptScore W2052803516C2778239845 @default.
- W2052803516 hasConceptScore W2052803516C2778248108 @default.
- W2052803516 hasConceptScore W2052803516C2780258809 @default.
- W2052803516 hasConceptScore W2052803516C2781182431 @default.
- W2052803516 hasConceptScore W2052803516C2781190966 @default.
- W2052803516 hasConceptScore W2052803516C2781451048 @default.
- W2052803516 hasConceptScore W2052803516C2908647359 @default.
- W2052803516 hasConceptScore W2052803516C29730261 @default.
- W2052803516 hasConceptScore W2052803516C71924100 @default.
- W2052803516 hasConceptScore W2052803516C90924648 @default.
- W2052803516 hasConceptScore W2052803516C99454951 @default.
- W2052803516 hasIssue "8" @default.
- W2052803516 hasLocation W20528035161 @default.
- W2052803516 hasOpenAccess W2052803516 @default.
- W2052803516 hasPrimaryLocation W20528035161 @default.
- W2052803516 hasRelatedWork W1997315384 @default.
- W2052803516 hasRelatedWork W2064052042 @default.
- W2052803516 hasRelatedWork W2090391825 @default.
- W2052803516 hasRelatedWork W2121726979 @default.
- W2052803516 hasRelatedWork W2132673884 @default.
- W2052803516 hasRelatedWork W2249980833 @default.
- W2052803516 hasRelatedWork W2378586341 @default.
- W2052803516 hasRelatedWork W2397387063 @default.
- W2052803516 hasRelatedWork W2439707001 @default.
- W2052803516 hasRelatedWork W2183797196 @default.
- W2052803516 hasVolume "2" @default.
- W2052803516 isParatext "false" @default.
- W2052803516 isRetracted "false" @default.
- W2052803516 magId "2052803516" @default.
- W2052803516 workType "article" @default.